The recent findings will shed light on the development of the treatment strategy, particularly revolving around the key therapeutic targets such as major cytokines (TNF-α, IL-1β), JAK-STAT, NF-κB and NLRP3 inflammasome signalling that hold the potential to cut off pathological reactions from mild to severe COVID-19 ARDS. This evidence concerns the gene NFKB1 and COVID-19.